Freeze of Gait Market Research Report Information By Type (Oral Dopaminergic Medication, Wearable and Walking Aid Devices, Deep Brain Stimulation, Others), End User (Hospitals, Clinics, Others) and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2032

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF PARKINSON’S DISEASE AND OTHER RELATED DISEASES

4.2.2 GROWING GERIATRIC POPULATION

4.2.3 INCREASING INVESTMENT IN R&D

4.3 RESTRAINTS

4.3.1 STRINGENT REGULATORY REQUIREMENTS

4.4 OPPORTUNITIES

4.4.1 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D AND DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION, MARKETING, AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 BARGAINING POWER OF SUPPLIERS

5.2.2 BARGAINING POWER OF BUYERS

5.2.3 THREAT OF NEW ENTRANTS

5.2.4 THREAT OF SUBSTITUTES

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT ANALYSIS OF COVID-19 ON FREEZE OF GAIT MARKET

5.3.1 OVERVIEW

5.3.2 IMPACT ON COST OF RAW MATERIALS AND PRODUCTS

5.3.3 IMPACT ON AVAILABILITY OF PRODUCTS

5.3.4 IMPACT ON ELECTIVE PROCEDURE

5.3.5 IMPACT ON SUPPLY CHAIN

6 GLOBAL FREEZE OF GAIT MARKET, BY TYPE

6.1 OVERVIEW

6.2 ORAL DOPAMINERGIC MEDICATION

6.3 WEARABLE AND WALKING AID DEVICES

6.4 DEEP BRAIN STIMULATION

6.5 OTHERS

7 GLOBAL FREEZE OF GAIT MARKET, BY END USER

7.1 OVERVIEW

7.2 HOSPITALS

7.3 CLINICS

7.4 OTHERS

8 GLOBAL FREEZE OF GAIT MARKET, BY REGION

8.1 NORTH AMERICA

8.1.1 US

8.1.2 CANADA

8.2 EUROPE

8.2.1 GERMANY

8.2.2 FRANCE

8.2.3 UK

8.2.4 ITALY

8.2.5 SPAIN

8.2.6 REST OF EUROPE

8.3 ASIA-PACIFIC

8.3.1 CHINA

8.3.2 INDIA

8.3.3 JAPAN

8.3.4 AUSTRALIA

8.3.5 SOUTH KOREA

8.3.6 REST OF ASIA-PACIFIC

8.4 REST OF THE WORLD

8.4.1 MIDDLE EAST

8.4.2 AFRICA

8.4.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 COMPETITIVE BENCHMARKING

9.3 MAJOR GROWTH STRATEGY IN FREEZE OF GAIT MARKET

9.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN FREEZE OF GAIT MARKET

9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.5.1 PARTNERSHIP & COLLABORATIONS

9.6 MAJOR PLAYERS SALES ANALYSIS

9.6.1 SALES & OPERATING INCOME

9.7 MAJOR PLAYERS R&D ANALYSIS

10 COMPANY PROFILES

10.1 VIATRIS INC.

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 PRODUCTS OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 GONDOLA MEDICAL TECHNOLOGIES SA

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 USTEP

10.3.1 COMPANY OVERVIEW

10.3.2 FINANCIAL OVERVIEW

10.3.3 PRODUCTS OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 KEY STRATEGIES

10.4 GYENNO TECHNOLOGIES CO., LTD.

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 SWOT ANALYSIS

10.4.6 KEY STRATEGIES

10.5 MEDEXO ROBOTICS

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 KEY STRATEGIES

10.6 TEVA PHARMACEUTICAL INDUSTRIES LTD.

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL ANALYSIS

10.6.3 PRODUCTS OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 SWOT ANALYSIS

10.6.6 KEY STRATEGIES

10.7 SUN PHARMACEUTICAL INDUSTRIES LTD

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 SWOT ANALYSIS

10.7.6 KEY STRATEGIES

10.8 WALK WITH PATH

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 KEY STRATEGIES

10.9 BEATS MEDICAL LIMITED

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 KEY STRATEGIES

10.10 AGILITAS

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 PRODUCTS OFFERED

10.10.4 KEY DEVELOPMENTS

10.10.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 GLOBAL FREEZE OF GAIT MARKET, BY TYPE, 2019–2032 (USD MILLION)

TABLE 4 GLOBAL FREEZE OF GAIT MARKET FOR ORAL DOPAMINERGIC MEDICATION, BY REGION, 2019–2032 (USD MILLION)

TABLE 5 GLOBAL FREEZE OF GAIT MARKET FOR WEARABLE AND WALKING AID DEVICES, BY REGION, 2019–2032 (USD MILLION)

TABLE 6 GLOBAL FREEZE OF GAIT MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2019–2032 (USD MILLION)

TABLE 7 GLOBAL FREEZE OF GAIT MARKET FOR OTHERS, BY REGION, 2019–2032 (USD MILLION)

TABLE 8 GLOBAL FREEZE OF GAIT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 9 GLOBAL FREEZE OF GAIT MARKET FOR HOSPITALS, BY REGION, 2019–2032 (USD MILLION)

TABLE 10 GLOBAL FREEZE OF GAIT MARKET FOR CLINICS, BY REGION, 2019–2032 (USD MILLION)

TABLE 11 GLOBAL FREEZE OF GAIT MARKET FOR OTHERS, BY REGION, 2019–2032 (USD MILLION)

TABLE 12 GLOBAL: FREEZE OF GAIT MARKET, BY REGION, 2019–2032 (USD MILLION)

TABLE 13 NORTH AMERICA MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2032 (USD MILLION)

TABLE 14 NORTH AMERICA: FREEZE OF GAIT MARKET, BY COUNTRY, 2019–2032 (USD MILLION)

TABLE 15 NORTH AMERICA: FREEZE OF GAIT MARKET, BY TYPE, 2019–2032 (USD MILLION)

TABLE 16 NORTH AMERICA: FREEZE OF GAIT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 17 US: FREEZE OF GAIT MARKET, BY TYPE, 2019–2032 (USD MILLION)

TABLE 18 US: FREEZE OF GAIT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 19 CANADA: FREEZE OF GAIT MARKET, BY TYPE, 2019–2032 (USD MILLION)

TABLE 20 CANADA: FREEZE OF GAIT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 21 EUROPE MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2032 (USD MILLION)

TABLE 22 EUROPE: FREEZE OF GAIT MARKET, BY COUNTRY, 2019–2032 (USD MILLION)

TABLE 23 EUROPE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2032 (USD MILLION)

TABLE 24 EUROPE: FREEZE OF GAIT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 25 GERMANY: FREEZE OF GAIT MARKET, BY TYPE, 2019–2032 (USD MILLION)

TABLE 26 GERMANY: FREEZE OF GAIT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 27 FRANCE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2032 (USD MILLION)

TABLE 28 FRANCE: FREEZE OF GAIT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 29 UK: FREEZE OF GAIT MARKET, BY TYPE, 2019–2032 (USD MILLION)

TABLE 30 UK: FREEZE OF GAIT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 31 ITALY: FREEZE OF GAIT MARKET, BY TYPE, 2019–2032 (USD MILLION)

TABLE 32 ITALY: FREEZE OF GAIT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 33 SPAIN: FREEZE OF GAIT MARKET, BY TYPE, 2019–2032 (USD MILLION)

TABLE 34 SPAIN: FREEZE OF GAIT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 35 REST OF EUROPE: FREEZE OF GAIT MARKET, BY TYPE, 2019–2032 (USD MILLION)

TABLE 36 REST OF EUROPE: FREEZE OF GAIT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 37 ASIA-PACIFIC MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2032 (USD MILLION)

TABLE 38 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 39 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 40 ASIA PACIFIC: FREEZE OF GAIT MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 41 CHINA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 42 CHINA: FREEZE OF GAIT MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 43 INDIA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 44 INDIA: FREEZE OF GAIT MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 45 JAPAN: FREEZE OF GAIT MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 46 JAPAN: FREEZE OF GAIT MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 47 AUSTRALIA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 48 AUSTRALIA: FREEZE OF GAIT MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 49 SOUTH KOREA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 50 SOUTH KOREA: FREEZE OF GAIT MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 51 REST OF ASIA-PACIFIC: FREEZE OF GAIT MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 52 REST OF ASIA-PACIFIC: FREEZE OF GAIT MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 53 REST OF THE WORLD MARKET ANALYSIS: FREEZE OF GAIT MARKET, 2019–2032 (USD MILLION)

TABLE 54 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY COUNTRY, 2018-2032 (USD MILLION)

TABLE 55 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 56 REST OF THE WORLD: FREEZE OF GAIT MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 57 MIDDLE EAST: FREEZE OF GAIT MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 58 MIDDLE EAST: FREEZE OF GAIT MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 59 AFRICA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 60 AFRICA: FREEZE OF GAIT MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 61 LATIN AMERICA: FREEZE OF GAIT MARKET, BY TYPE, 2018-2032 (USD MILLION)

TABLE 62 LATIN AMERICA: FREEZE OF GAIT MARKET, BY END USER, 2018-2032 (USD MILLION)

TABLE 63 MAJOR MANUFACTURERS IN FREEZE OF GAIT MARKET

TABLE 64 MOST ACTIVE PLAYER IN FREEZE OF GAIT MARKET

TABLE 65 PARTNERSHIP & COLLABORATIONS

TABLE 66 VIATRIS INC.: PRODUCTS OFFERED

TABLE 67 GONDOLA MEDICAL TECHNOLOGIES SA: PRODUCTS OFFERED

TABLE 68 GONDOLA MEDICAL TECHNOLOGIES SA: KEY DEVELOPMENTS

TABLE 69 USTEP: PRODUCTS OFFERED

TABLE 70 GYENNO TECHNOLOGIES CO., LTD.: PRODUCTS OFFERED

TABLE 71 MEDEXO ROBOTICS: PRODUCTS OFFERED

TABLE 72 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED

TABLE 73 SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCTS OFFERED

TABLE 74 WALK WITH PATH: PRODUCTS OFFERED

TABLE 75 BEATS MEDICAL LIMITED: PRODUCTS OFFERED

TABLE 76 AGILITAS: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL FREEZE OF GAIT MARKET

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: GLOBAL FREEZE OF GAIT MARKET

FIGURE 5 DRIVERS: IMPACT ANALYSIS

FIGURE 6 RESTRAINT: IMPACT ANALYSIS

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL FREEZE OF GAIT MARKET

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL FREEZE OF GAIT MARKET

FIGURE 9 GLOBAL FREEZE OF GAIT MARKET, BY TYPE, 2022 & 2032 (USD MILLION)

FIGURE 10 GLOBAL FREEZE OF GAIT MARKET, BY TYPE, SEGMENT SHARE, 2022

FIGURE 11 GLOBAL FREEZE OF GAIT MARKET, BY END USER, 2022 & 2032 (USD MILLION)

FIGURE 12 GLOBAL FREEZE OF GAIT MARKET, BY END USER, SEGMENT SHARE, 2022

FIGURE 13 GLOBAL FREEZE OF GAIT MARKET, BY REGION, 2022 & 2032 (USD MILLION)

FIGURE 14 GLOBAL: FREEZE OF GAIT MARKET SHARE (%), BY REGION, 2022

FIGURE 15 NORTH AMERICA: FREEZE OF GAIT MARKET SHARE (%), BY REGION 2022

FIGURE 16 EUROPE: FREEZE OF GAIT MARKET SHARE, BY REGION 2022 (%)

FIGURE 17 ASIA PACIFIC: FREEZE OF GAIT MARKET SHARE, BY COUNTRY, 2022 (%)

FIGURE 18 REST OF THE WORLD: FREEZE OF GAIT MARKET SHARE, BY COUNTRY, 2022 (%)

FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN FREEZE OF GAIT MARKET

FIGURE 21 MAJOR PLAYERS SALES & OPERATING INCOME, 2022

FIGURE 22 MAJOR PLAYERS R&D EXPENDITURE, 2022

FIGURE 23 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 VIATRIS INC.: SWOT ANALYSIS

FIGURE 25 GONDOLA MEDICAL TECHNOLOGIES SA: SWOT ANALYSIS

FIGURE 26 GYENNO TECHNOLOGIES CO., LTD.: SWOT ANALYSIS

FIGURE 27 TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS

FIGURE 29 SUN PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS